Novo Nordisk A/S (NYSE:NVO) Sees Significant Decrease in Short Interest

Key Points

• Short interest fell 14.6% in April to 17,019,927 shares (about 0.4% of shares outstanding), leaving a short-interest ratio of roughly 1.1 days based on average daily volume.
• Positive near-term catalysts include an FDA proposal to restrict mass compounding of GLP‑1 ingredients and Novo Nordisk beginning shipments of its oral Ozempic tablets in the U.S. on May 4, with distribution wins (WeightWatchers Med+, GoodRx) expected to support uptake.
• However, competitive risks are mounting as Canada approved a second generic semaglutide and Eli Lilly’s new oral GLP‑1 rollout plus broader pricing pressure could weigh on Novo’s volumes and margins.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totaling 17,019,927 shares, a decrease of 14.6% from the March 31st total of 19,927,815 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average daily volume of 15,265,377 shares, the short-interest ratio is currently 1.1 days.

Institutional Trading of Novo Nordisk A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Simplicity Wealth LLC boosted its position in Novo Nordisk A/S by 16.0% during the first quarter. Simplicity Wealth LLC now owns 6,216 shares of the company's stock worth $228,000 after purchasing an additional 857 shares in the last quarter. Manning & Napier Advisors LLC boosted its position in Novo Nordisk A/S by 3.7% during the first quarter. Manning & Napier Advisors LLC now owns 173,167 shares of the company's stock worth $6,364,000 after purchasing an additional 6,235 shares in the last quarter. Whipplewood Advisors LLC boosted its position in Novo Nordisk A/S by 56.4% during the first quarter. Whipplewood Advisors LLC now owns 1,680 shares of the company's stock worth $62,000 after purchasing an additional 606 shares in the last quarter. Summit Securities Group LLC purchased a new position in Novo Nordisk A/S during the first quarter worth approximately $125,000. Finally, Mosaic Family Wealth Partners LLC boosted its position in Novo Nordisk A/S by 406.4% during the first quarter. Mosaic Family Wealth Partners LLC now owns 19,911 shares of the company's stock worth $732,000 after purchasing an additional 15,979 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA moves to restrict mass compounding of GLP‑1 active ingredients, which would make it harder for copycat/compounded alternatives to scale and should help protect branded pricing and volumes. FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Novo will start shipping its oral Ozempic (semaglutide) tablets in the U.S. on May 4, expanding its addressable market beyond injectables and helping defend diabetes sales as pricing pressure mounts. Ozempic pill available in US
• Positive Sentiment: Distribution/access wins (WeightWatchers Med+ and GoodRx adding the Ozempic pill) should support uptake and patient access for the oral launch. WeightWatchers expands access to Ozempic pill
• Neutral Sentiment: Analysts’ consensus still shows material upside vs. the current price (average target ~$65.56) and small EPS estimate tweaks from Erste Group — supportive context but not immediate drivers. Analyst price targets
• Negative Sentiment: Canada approved a second generic semaglutide (Apotex), signaling increasing global generic competition that could undercut Novo’s pricing and margins in core markets over time. Canada approves second generic version of Ozempic
• Negative Sentiment: Eli Lilly’s Q1 beat, raised guidance and approval/rollout of Foundayo (an easier-to-take oral GLP‑1) widen competitive pressure on Novo’s weight‑loss franchise and could lead to share loss. Lilly's Double-Beat Widens the GLP-1 Gap
• Negative Sentiment: Ongoing concerns around pricing pressure and margin compression in the GLP‑1 market could make NVO’s recent rebound vulnerable if generics and convenience-focused rivals keep gaining traction. Pricing pressure and falling margins analysis

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded up $1.62 during midday trading on Friday, hitting $43.84. 26,213,797 shares of the company were exchanged, compared to its average volume of 22,312,807. The firm has a market capitalization of $195.76 billion, a PE ratio of 12.64, a price-to-earnings-growth ratio of 9.57 and a beta of 0.73. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44. The business has a fifty day simple moving average of $38.50 and a two-hundred day simple moving average of $47.33. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.34 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were issued a dividend of $1.2751 per share. This represents a yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S's dividend payout ratio (DPR) is 50.43%.

Analyst Ratings Changes

NVO has been the topic of a number of research reports. Kepler Capital Markets lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Tuesday, February 24th. Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an "outperform" rating and a $175.00 price objective on the stock. Jefferies Financial Group raised Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a report on Thursday, February 12th. Wolfe Research initiated coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They issued a "peer perform" rating on the stock. Finally, Zacks Research raised Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 10th. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.